A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Akron Molecules AG
- Target Recruit Count
- 266
- Registration Number
- NCT02003118
- Locations
- 🇦🇹
Clinical study center, Vienna, Austria
© Copyright 2025. All Rights Reserved by MedPath